Recently, one study showed the development of CD19-relapsed was not eliminated in R/R ALL patients treated with CD22 CAR T cell therapy who relapsed after CD19 CAR T cell therapy (34). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.